Tirzepatide
Dual GIP/GLP-1 receptor agonist representing the next generation of metabolic health therapeutics.
Consulta al por Mayor
10+ viales · OEM / Marca Privada · Envío en Cadena de Frío
Cotización de Fábrica por WhatsAppPrecios por Volumen
Descuentos aplicados mediante cotización por WhatsApp para consultas calificadas de investigación / clínicas.
Tirzepatide is a first-in-class dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. This innovative molecule activates two key incretin pathways, providing enhanced metabolic benefits. Available in multiple dosage strengths: 2.5mg, 5mg, 7.5mg, 15mg, 20mg, and 30mg for flexible dosing protocols.
Available Dosages
2.5mg
Starting dose for initiation
Key Benefits
- Dual GIP/GLP-1 receptor activation
- Enhanced metabolic health support
- Multiple dosing options: 2.5mg to 30mg
- Next-generation metabolic therapeutic
- Supports comprehensive weight management
- Evidence-based formulation
Scientific Background
Tirzepatide represents a breakthrough in metabolic medicine by simultaneously activating both GIP and GLP-1 receptors. Clinical trials have shown superior efficacy compared to single-agonist therapies, with significant improvements in metabolic health markers.
Educational Display Only
This product information is for educational purposes. Always consult licensed healthcare providers for personalized medical advice.
Frequently Asked Questions
Related Educational Guides
Explore Related Topics
Browse by Category
Related Topics
Related Products
NAD+
Cellular health supplement supporting NAD+ levels, a crucial coenzyme involved in energy metabolism and cellular repair processes.
Available: 100mg, 200mg, 500mg
Semaglutide
GLP-1 receptor agonist for metabolic health optimization, supporting healthy weight management and glucose metabolism.
Available: 0.25mg, 0.5mg, 1mg
Tirzepatide 2.5mg
Tirzepatide 2.5mg starting-dose research vial — entry-level dual GIP/GLP-1 receptor agonist for pilot studies and dose-titration protocols.